About: Milton Weinstein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Milton Weinstein Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

American health scientist

Attributes	Values
rdf:type	Item
description	American health scientist (en)
rdfs:label	Milton Weinstein (en) Milton Weinstein (es) Milton Weinstein (nl) Milton Weinstein (ast)
skos:prefLabel	Milton Weinstein (en) Milton Weinstein (es) Milton Weinstein (nl) Milton Weinstein (ast)
name	Milton Weinstein (en) Milton Weinstein (es) Milton Weinstein (nl) Milton Weinstein (ast)
given name	wds:Q30223679-1E81882A-7891-457E-8197-B729B32B1064
given name	Milton
instance of	wds:Q30223679-12D6424E-BB37-49DB-8C3B-596E509CBB57
instance of	Homo sapiens
Google Knowledge Graph ID	wds:Q30223679-4D0A8BF1-E201-4F28-83B5-2EB43071EFEA
Google Knowledge Graph ID	http://g.co/kg/g/11g7zgygfq
Google Knowledge Graph ID	/g/11g7zgygfq
skos:altLabel	Milton C. Weinstein (en)
employer	wds:Q30223679-837BEC0D-D705-4DC6-A89E-E70CB7A8A016
CiNii Research ID	wds:Q30223679-48C530F4-0961-4ECF-B49D-8A99E398C97F
sex or gender	wds:Q30223679-EE77980A-B1B7-44C1-8680-238FE4FC3630
ISNI	wds:Q30223679-57EC2E04-CC5B-47DE-8855-6D6DB5FEA994
VIAF ID	wds:Q30223679-4A3E8873-6706-4F39-8406-279A72801CF1
Library of Congress authority ID	wds:Q30223679-EA8F177B-5DB3-4578-8F80-F3184C84B607
NACSIS-CAT author ID	wds:Q30223679-AE71D1F6-6DDC-41FD-B508-1D01CD895A81
SHARE Catalogue author ID	wds:Q30223679-8FA5FB24-2C45-444E-A1F5-587D14A64510
educated at	wds:Q30223679-867AF6EE-2EE9-4B6F-8640-852D295E3A8A
National Library of Israel J9U ID	wds:Q30223679-08579CC1-8BF0-4AA5-9871-40910423588F
CiNii Research ID	https://cir.nii.ac.jp/crid/1140282266597694976.rdf
VIAF ID	http://viaf.org/viaf/108746290
Library of Congress authority ID	http://id.loc.gov/authorities/names/n80022837
NACSIS-CAT author ID	https://ci.nii.ac.jp/author/DA01088459#entity
employer	Harvard University
CiNii Research ID	1140282266597694976
sex or gender	male
ISNI	0000000084616654
VIAF ID	108746290
Library of Congress authority ID	n80022837
NACSIS-CAT author ID	DA01088459
SHARE Catalogue author ID	504521
educated at	Harvard University
National Library of Israel J9U ID	987007315193405171
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q30223679 Milton Weinstein
is author of	Medicare and cost-effectiveness analysis Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. The global cost of nonoptimal blood pressure. What Do Patients Value? The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients Foundations of Cost-Effectiveness Analysis for Health and Medical Practices Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines The cost-effectiveness of preventing AIDS-related opportunistic infections The survival benefits of AIDS treatment in the United States The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis Cost-effectiveness of computed tomography screening for lung cancer in the United States Use and misuse of the term "cost effective" in medicine Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population Comparative effectiveness and health care spending--implications for reform Outcomes and costs of acute treatment of traumatic brain injury. Preferences for health outcomes. Comparison of assessment methods Scaling up antiretroviral therapy in South Africa: the impact of speed on survival The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. The cost effectiveness of combination antiretroviral therapy for HIV disease. The cost of a successful delivery with in vitro fertilization. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics Cost and health implications of cholesterol lowering Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine Cost-effectiveness of coronary artery bypass surgery Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis When does quality-adjusting life-years matter in cost-effectiveness analysis? Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Legislating against use of cost-effectiveness information Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial Annual financial impact of well-differentiated thyroid cancer care in the United States Pertussis Vaccine — An Analysis of Benefits, Risks and Costs Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine Should the arteriovenous fistula be created before starting dialysis?: a decision analytic approach The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis Cost-effectiveness of HIV treatment as prevention in serodiscordant couples

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software